Quarterly ResultJul 23, 2026, 06:16 AM
Gentherm Q2 Revenue $416.2M; New $400M Buyback; Guidance Raised
AI Summary
Gentherm Inc. announced strong financial results for the second quarter of 2026, with product revenues increasing 11.0% to $416.2 million and adjusted diluted EPS rising to $0.75. The company also raised its full-year 2026 guidance for product revenues and Adjusted EBITDA, reflecting confidence in continued performance. Additionally, the Board authorized a new $400 million stock repurchase program, replacing the previous one, and provided an update on its strategic medical acquisition and the ongoing merger with Modine Performance Technologies.
Key Highlights
- Board authorized a new $400 million stock repurchase program, expiring July 27, 2029.
- Terminated the 2024 stock repurchase program, with $110.1 million remaining as of June 30, 2026.
- Q2 2026 product revenues increased 11.0% to $416.2 million from $375.1 million YoY.
- Q2 2026 net income was $4.4 million, compared to $0.5 million in the prior year.
- Q2 2026 adjusted diluted earnings per share was $0.75, up from $0.54 YoY.
- Raised full-year 2026 product revenue guidance to $1.55B-$1.65B from $1.5B-$1.6B.
- Raised full-year 2026 Adjusted EBITDA guidance to $185M-$200M from $175M-$195M.
- Acquired Innovative Medical Equipment, LLC, expanding the medical product portfolio.
- Merger with Modine Performance Technologies remains on track to close by early Q4 2026.
Price Impact
More from THRM